person · Reporting owner
Primiano Christopher Brett
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aura Biosciences, Inc.AURA · Entity 5142 | Chief Business Officer | October 28, 2021 | October 29, 2021 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | EVP, CBO, GC & Secretary | December 01, 2020 | December 03, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aura Biosciences, Inc.
Report date October 28, 2021 · Filed October 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,750 |
Reported balance
After 2021-10-28 transaction · row 1
1 source rowRow 1 · 2021-10-28 · Grant · Acquired 8,750 · Balance 8,750 F1: These shares were acquired pursuant to a restricted stock unit award under the Company's 2021 Stock Option and Incentive Plan. Each restricted stock unit represents the right to receive one share of the Company's common stock. These restricted stock units vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2031-10-27 | Direct | 37,500 |
Reported balance
After 2021-10-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-10-28 · Grant · Acquired 37,500 · Balance 37,500 F2: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of October 28, 2022 with the remainder vesting thereafter in annual installments. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired pursuant to a restricted stock unit award under the Company's 2021 Stock Option and Incentive Plan. Each restricted stock unit represents the right to receive one share of the Company's common stock. These restricted stock units vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant.
F2: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of October 28, 2022 with the remainder vesting thereafter in annual installments.
Karyopharm Therapeutics Inc.
Report date December 01, 2020 · Filed December 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,523 |
Ending reported balance
After 2020-12-01 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2020-12-01 · Exercise / conversion · Acquired 78,124 · Balance 82,647 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Row 2 · 2020-12-01 · Sale · Disposed 78,124 · Balance 4,523 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Row 3 · 2020-12-01 · Exercise / conversion · Acquired 58,937 · Balance 63,460 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Row 4 · 2020-12-01 · Sale · Disposed 58,937 · Balance 4,523 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.45 · Expires 2028-01-23 | Direct | 46,876 |
Reported balance
After 2020-12-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-12-01 · Exercise / conversion · Disposed 78,124 · Balance 46,876 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 24, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.39 · Expires 2027-01-19 | Direct | 16,842 |
Reported balance
After 2020-12-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-12-01 · Exercise / conversion · Disposed 58,937 · Balance 16,842 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 24, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F3: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2018 Filed Mar 6, 2018 21:54 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,500 | $16.03 | $40,076.00 |
DisclosureSEC source: 0001209191-18-017330 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,881 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.06, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each price. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 1,486 | $15.01 | $22,298.02 |
DisclosureSEC source: 0001209191-18-011324 · doc4.xml · nonDerivative · entry 2 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,381 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. These shares were sold in transactions at $15.00 and $15.08. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each price. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 1,014 | $15.02 | $15,228.96 |
DisclosureSEC source: 0001209191-18-011324 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,867 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.04, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each price. Read SEC document |
| February 07, 2018 Filed Feb 8, 2018 21:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 1,500 | $13.00 | $19,500.00 |
DisclosureSEC source: 0001209191-18-008420 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,881 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 21:29 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001209191-18-005380 · doc4.xml · derivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: This option was granted on January 24, 2018. The shares underlying this option vest as to 25% of the shares on January 24, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:04 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $6.54 | $0.00 |
DisclosureSEC source: 0001209191-17-065406 · doc4.xml · derivative · entry 5 Primiano Christopher Brett · CIK 0001603510 · SVP, OPS, BUS DEV, GC & SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 17,000 shares Expires 2026-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 15, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:04 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 644 | $9.59 | $6,172.93 |
DisclosureSEC source: 0001209191-17-065406 · doc4.xml · nonDerivative · entry 4 Primiano Christopher Brett · CIK 0001603510 · SVP, OPS, BUS DEV, GC & SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,381 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at $9.56 and $9.59. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:04 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 16,356 | $9.93 | $162,442.89 |
DisclosureSEC source: 0001209191-17-065406 · doc4.xml · nonDerivative · entry 3 Primiano Christopher Brett · CIK 0001603510 · SVP, OPS, BUS DEV, GC & SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,025 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.60 to $10.59, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:04 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 17,000 | $6.54 | $111,180.00 |
DisclosureSEC source: 0001209191-17-065406 · doc4.xml · nonDerivative · entry 2 Primiano Christopher Brett · CIK 0001603510 · SVP, OPS, BUS DEV, GC & SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 21:04 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,042 | $10.88 | $109,255.96 |
DisclosureSEC source: 0001209191-17-065406 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · SVP, OPS, BUS DEV, GC & SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,381 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.68 to $11.15, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 21:03 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 4,958 | $11.25 | $55,755.19 |
DisclosureSEC source: 0001209191-17-059944 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · SVP, OPS, BUS DEV, GC & SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,423 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 6, 2017 and November 7, 2017 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| November 05, 2017 Filed Nov 6, 2017 21:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-059396 · doc4.xml · derivative · entry 2 Primiano Christopher Brett · CIK 0001603510 · SVP, OPS, BUS DEV, GC & SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F2 · derivative.exercise_date: On November 5, 2015, the reporting person was granted 30,000 restricted stock units. 50% of the restricted stock units vested on November 5, 2016. The remaining 50% of the restricted stock units vested on November 5, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F2 · derivative.expiration_date: On November 5, 2015, the reporting person was granted 30,000 restricted stock units. 50% of the restricted stock units vested on November 5, 2016. The remaining 50% of the restricted stock units vested on November 5, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document |
| November 05, 2017 Filed Nov 6, 2017 21:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-059396 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · SVP, OPS, BUS DEV, GC & SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 1,500 | $12.00 | $18,000.00 |
DisclosureSEC source: 0001209191-17-055750 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · SVP, OPS, BUS DEV, GC & SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,381 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 20:09 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,000 | $11.00 | $22,000.00 |
DisclosureSEC source: 0001209191-17-053148 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · SVP, OPS, BUS DEV, GC & SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,881 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 29, 2017 Filed Aug 30, 2017 20:09 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,195 | $10.00 | $21,950.00 |
DisclosureSEC source: 0001209191-17-050698 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · SVP, OPS, BUS DEV, GC & SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,686 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 2,062 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan. Read SEC document |
| June 26, 2017 Filed Sep 1, 2017 21:43 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 805 | $10.03 | $8,071.01 |
DisclosureSEC source: 0001209191-17-051076 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · SVP, OPS, BUS DEV, GC & SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,881 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in transactions at $10.00 and $10.07. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each price. F3 · balance_after: Amount also reflects the number of shares sold by the reporting person as previously reported on the Form 4 filed on August 30, 2017 (the "Previous Form 4") as well as the acquisition of 2,062 shares under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan, which was previously disclosed on the Previous Form 4. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 22:38 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 118,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001209191-17-005326 · doc4.xml · derivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · SVP, OPS, BUS DEV, GC & SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,000 Underlying: Common Stock · 118,000 shares Expires 2027-01-19 F1 · derivative.exercise_date: This option was granted on January 20, 2017. The shares underlying this option vest as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 22:48 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 4,342 | $8.19 | $35,544.48 |
DisclosureSEC source: 0001209191-16-149846 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · SVP,CORP DEV,GEN COUNSEL&SEC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,819 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 8, 2016 and November 9, 2016 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| November 05, 2016 Filed Nov 8, 2016 21:09 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-148843 · doc4.xml · derivative · entry 2 Primiano Christopher Brett · CIK 0001603510 · SVP,CORP DEV,GEN COUNSEL&SEC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F3 · derivative.exercise_date: On November 5, 2015, the reporting person was granted 30,000 restricted stock units. 50% of the restricted stock units vested on November 5, 2016, and the remaining 50% of the restricted stock units will vest on November 5, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: On November 5, 2015, the reporting person was granted 30,000 restricted stock units. 50% of the restricted stock units vested on November 5, 2016, and the remaining 50% of the restricted stock units will vest on November 5, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document |
| November 05, 2016 Filed Nov 8, 2016 21:09 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-148843 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · SVP,CORP DEV,GEN COUNSEL&SEC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F2 · balance_after: Includes 4,161 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.